Syn-Ake
Also known as: Dipeptide Diaminobutyroyl Benzylamide Diacetate, Snake venom peptide mimic, Waglerin-1 analog
Overview
Syn-Ake is a synthetic tripeptide analog of Waglerin-1, the main neurotoxic peptide from the venom of the temple pit viper Tropidolaemus wagleri. Like its natural template, Syn-Ake antagonizes muscular nicotinic acetylcholine receptors (nAChRs) in a reversible, competitive manner, reducing the intensity and frequency of facial muscle contractions without causing true neurotoxicity. Applied topically, it is marketed as a 'snake venom in a cream' cosmeceutical for smoothing expression lines, and clinical studies support improvements in wrinkle appearance.
Mechanism of Action
Syn-Ake binds the muscular nicotinic acetylcholine receptor (nAChR, α1β1γδ subunit composition) at the acetylcholine binding site, acting as a competitive reversible antagonist. This reduces postsynaptic membrane depolarization in response to acetylcholine release, attenuating muscle contraction strength at neuromuscular junctions in facial skin. The effect is dose-dependent, reversible, and localized to the dermis upon topical application, unlike systemic nAChR antagonists.
Potential Benefits
- Reduction of wrinkle depth in expression lines
- Reversible muscle relaxation at neuromuscular junctions
- Clinical studies show improvement in glabellar and periorbital lines
- Complementary mechanism to Argireline (pre/post-synaptic combination)
- Good cosmeceutical safety profile
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 2% SYN-AKE serum 1x daily |
| Intermediate | 4% SYN-AKE serum 2x daily |
| Advanced | 4% SYN-AKE combined with Argireline and Matrixyl |
| Cycle Duration | Continuous cosmetic use |
Dipeptide diaminobutyroyl benzylamide diacetate. Mimics Waglerin-1 snake venom — nAChR antagonist.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Topical (serum/cream) Limited penetration — superficial action
Apply to expression lines.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Syn-Ake:
'Topical Botox' Stack
Combined neuromuscular-modulating and collagen-stimulating cosmetic peptides.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Store at room temperature, away from light and heat |
|---|
Topical/cosmetic peptide — comes pre-formulated. No reconstitution needed.
Need exact syringe measurements?
Amino Acid Sequence
Dipeptide Diaminobutyroyl Benzylamide Diacetate (non-standard residues)
Side Effects & Safety
- Well-tolerated topically
- Rare skin sensitization
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store cream/serum at room temperature away from direct sunlight and heat. Refrigeration optional to extend shelf life. |
Synergistic Compounds
The following compounds have been studied alongside Syn-Ake for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.